Swedish Orphan Biovitrum AB, commonly known as Sobi, is a leading biopharmaceutical company headquartered in Sweden (SE). Founded in 1991, Sobi has established itself as a key player in the biotechnology industry, focusing on rare diseases and specialty care. With a strong operational presence across Europe, North America, and the Asia-Pacific region, Sobi is dedicated to developing innovative therapies that address unmet medical needs. Sobi's core product portfolio includes treatments for haemophilia, inflammation, and genetic disorders, distinguished by their commitment to patient-centric solutions and advanced biopharmaceutical technologies. The company has achieved significant milestones, including strategic partnerships and a robust pipeline of therapies, solidifying its market position as a trusted provider in the rare disease sector. Sobi continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by complex health conditions.
How does Swedish Orphan Biovitrum's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Swedish Orphan Biovitrum's score of 54 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Swedish Orphan Biovitrum AB (Sobi) reported total carbon emissions of approximately 253,324,000 kg CO2e. This includes Scope 1 emissions of about 1,097,000 kg CO2e, primarily from mobile combustion (approximately 1,048,000 kg CO2e), and Scope 2 emissions of about 771,000 kg CO2e, with purchased electricity contributing approximately 539,000 kg CO2e. The majority of Sobi's emissions are from Scope 3, totalling about 251,456,000 kg CO2e, which includes significant contributions from purchased goods and services (approximately 216,133,000 kg CO2e). In 2023, Sobi's total emissions were approximately 194,977,000 kg CO2e, with Scope 1 emissions at about 1,053,000 kg CO2e and Scope 2 emissions at approximately 815,000 kg CO2e. The company has set ambitious targets to reduce its operational greenhouse gas footprint to net zero emissions by 2030 for both Scope 1 and Scope 2 emissions. Additionally, Sobi aims for a 37.8% absolute reduction in combined Scope 1 and 2 emissions from a 2023 baseline by 2029. Sobi is committed to ensuring that 65% of its suppliers, by spend, covering purchased goods and services and upstream transportation and distribution, will have science-based targets by FY2029. These commitments align with the Science Based Targets initiative (SBTi) and reflect Sobi's dedication to addressing climate change within the pharmaceutical and biotechnology sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 150,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,450,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | 000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Swedish Orphan Biovitrum is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
